医学
杜拉鲁肽
内科学
内分泌学
脂联素
安慰剂
2型糖尿病
胰高血糖素样肽1受体
糖尿病
兴奋剂
利拉鲁肽
人口
胰岛素抵抗
胃肠病学
受体
病理
替代医学
环境卫生
作者
Mark L. Hartman,Arun J. Sanyal,Rohit Loomba,Jonathan M. Wilson,Amir Nikooienejad,Ross Bray,Chrisanthi A. Karanikas,Kevin L. Duffin,Deborah A. Robins,Axel Haupt
出处
期刊:Diabetes Care
[American Diabetes Association]
日期:2020-04-14
卷期号:43 (6): 1352-1355
被引量:151
摘要
OBJECTIVE To determine the effect of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 receptors, on biomarkers of nonalcoholic steatohepatitis (NASH) and fibrosis in patients with type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS Patients with T2DM received either once weekly tirzepatide (1, 5, 10, or 15 mg), dulaglutide (1.5 mg), or placebo for 26 weeks. Changes from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST), keratin-18 (K-18), procollagen III (Pro-C3), and adiponectin were analyzed in a modified intention-to-treat population. RESULTS Significant (P < 0.05) reductions from baseline in ALT (all groups), AST (all groups except tirzepatide 10 mg), K-18 (tirzepatide 5, 10, 15 mg), and Pro-C3 (tirzepatide 15 mg) were observed at 26 weeks. Decreases with tirzepatide were significant compared with placebo for K-18 (10 mg) and Pro-C3 (15 mg) and with dulaglutide for ALT (10, 15 mg). Adiponectin significantly increased from baseline with tirzepatide compared with placebo (10, 15 mg). CONCLUSIONS In post hoc analyses, higher tirzepatide doses significantly decreased NASH-related biomarkers and increased adiponectin in patients with T2DM.
科研通智能强力驱动
Strongly Powered by AbleSci AI